Clinical trials: Follow-up
Multiple Sclerosis
BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study
This study will primarily compare the long-term effects of an early and continued treatment with Betaferon/Betaseron (patients who were treated with active medication during the double-blind BENEFIT study) to treatment initiated…
- Trial name
- NCT00185211
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- 94 sites in Austria, Belgium and 18 more
- Volunteers
- 468 people
- Sponsor
- Bayer
Liver Transplant
A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients.
Assuming greater efficacy in the prevention of acute rejection in the EVR arm with minimisation of TAC levels, the hypothesis of the present trial was that the introduction of EVR in combination with the minimisation of TAC…
- Trial name
- REDUCE (NCT02040584)
- Testing
- Minimisation of TAC, TAC + MMF + corticosteroids
- Where
- 20 sites in Spain
- Volunteers
- 217 people
- Sponsor
- Novartis Pharmaceuticals
Non-muscle-invasive Bladder Cancer
A Multi-National Study In Bladder Cancer Patients to Detect Recurrences After TURB (Trans-urethral Resection of the Bladder) Earlier With the Xpert Bladder Cancer Monitor Assay (ANTICIPATE X)
Bladder cancer is the 5th most common cancer in Europe, with more than 151,000 new cases diagnosed in 2012 (4% of the total). Bladder cancer has the highest recurrence rate of any malignancy, often as high as 70% within 5 years…
- Trial name
- ANTICIPATE X (NCT03664258)
- Testing
- Xpert Bladder Cancer Monitor
- Where
- 13 sites in Austria, Czechia and 7 more
- Volunteers
- 852 people
- Sponsor
- Cepheid
ACL Rupture
Clinical Performance and Safety of ENDOPACK® DT4-EBMCA in ACL Reconstruction 24 Months Post-surgery
Anterior cruciate ligament (ACL) injuries are among the most common sports-related knee traumas. The DT4-EBMCA device, based on a quadrupled semitendinosus autograft technique, aims to provide effective and minimally invasive…
- Trial name
- DT4-EBMCA (NCT06990100)
- Testing
- ACL surgery
- Where
- France
- Volunteers
- 36 people
- Sponsor
- SACIMEX
Knee Pain Chronic, Osteoarthritis, Knee
Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty)
The main objective of the study is to evaluate the safety, performance and clinical benefits of the Persona implant and its instrumentation in primary total knee arthroplasty
- Conditions
- Knee Pain Chronic, Osteoarthritis, Knee, Rheumatoid Arthritis, Traumatic Arthritis
- Trial name
- NCT05787821
- Testing
- Total Knee Arthroplasty
- Where
- 16 sites in United States
- Volunteers
- 760 people
- Sponsor
- Zimmer Biomet
Degenerative Osteoarthritis, Rheumatoid Arthritis
VEGA Prospective Kiel
Voluntary Post-Marketing Clinical Follow-up (PMCF) as part of the post marketing surveillance plan for the product under investigation.
- Trial name
- NCT02802085
- Testing
- VEGA Knee
- Where
- Germany
- Volunteers
- 84 people
- Sponsor
- Aesculap AG
Hepatitis C, Chronic, Hepacivirus
Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)
Study P05063 is a 3-year long-term follow-up (LTFU) study in participants previously treated with boceprevir (BOC) or narlaprevir (NAR) in a Phase 1, 2, or 3 clinical study.
- Trial name
- NCT00689390
- Testing
- Boceprevir, Narlaprevir, Peginterferon alfa-2b
- Volunteers
- 1,954 people
- Sponsor
- Merck Sharp & Dohme LLC
Tooth Loss, Ceramic Implant
PMCF Study of CeraRoot Ceramic Implants One-piece: 3 Years Follow up
The main objective is to evaluate the success / failure rate of CeraRoot ceramic implants (one piece) during three year follow up.
- Trial name
- NCT04598776
- Where
- Spain
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- CeraRoot SL
Multiple Sclerosis
Correlation Between Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) in Patients With Multiple Sclerosis (MS) in Argentina
This observational study is being conducted to evaluate the usefulness of the MSFC and its relationship with EDSS scores in subjects with MS in Argentina.
- Trial name
- NCT01080014
- Where
- Argentina
- Volunteers
- 252 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Growth Hormon Deficiency, Turner Syndrome in Pre-pubertal Children
Long Term Follow up Study of Predictive Markers in GHD and TS Children
Primary objective is to assess the relationship between changes from serum biomarkers observed after 1 month of Saizen® therapy and change in height, weight after up to 5 years of treatment with Growth Hormone in children with…
- Trial name
- PREDICT LT FUP (NCT00699855)
- Volunteers
- 182 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Alzheimer's Disease
Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07
This study is designed to test the relationship between measurements of brain amyloid using florbetapir F 18 PET imaging and true levels of amyloid plaque density as measured by histopathological assessment.
- Trial name
- NCT01447719
- Testing
- florbetapir F 18
- Where
- 22 sites in United States
- Volunteers
- 110 people
- Sponsor
- Avid Radiopharmaceuticals
Open-Angle Glaucoma or Ocular Hypertension, Ocular Surface Disease
A Phase III Multinational Multicenter Investigator-Masked Randomized Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular Hypertension
A Phase III, Multinational, Multicenter, Investigator-Masked, Randomized, Active-Controlled Trial, comparing the efficacy and safety of DE-130A with Xalatan® in Patients with Open-Angle Glaucoma or Ocular Hypertension over a…
- Trial name
- NCT04133311
- Testing
- DE-130A, Xalatan®, DE-130A/DE-130A
- Where
- France
- Volunteers
- 386 people
- Sponsor
- Santen SAS
Any Patient Treated With MB-105
A Long-term Follow-up Study of Patients Who Received MB-105
This study is to fulfil the regulatory requirement for 15-year follow-up for patients treated with MB-105 in any study
- Trial name
- NCT07340814
- Testing
- MB-105
- Volunteers
- 40 people
- Sponsor
- March Biosciences Inc
Stargardt's Macular Dystrophy
A Follow up Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)
The purpose of this study is to evaluate the long term safety and tolerability of hESC-RPE cellular therapy in patients with advanced SMD from 1 to 5 years following the surgical procedure to implant the hESC-RPE cells.
- Trial name
- NCT02941991
- Testing
- hESC-RPE
- Where
- 2 sites in United Kingdom
- Volunteers
- 12 people
- Sponsor
- Astellas Institute for Regenerative Medicine
Rhinitis Sicca
A Post-Market Clinical Follow-up Investigation to Verify Performance and Safety of Viiral®Nasal Spray in Subjects With Dry Nose Symptoms
A chronic irritation of the nasal mucosa can be painful and unpleasant for the individual. Dry nasal mucosa with scabs is a common problem but not everyone seeks care.
- Trial name
- NCT05264350
- Testing
- Sialic acid nasal spray, Isotonic Saline Nasal Spray
- Where
- 2 sites in Sweden
- Volunteers
- 84 people
- Sponsor
- Viiral Nordic AB
Urinary Bladder, Overactive, Spinal Cord Injury
Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy
The aim of this study is to continue following participants who have received EG110A during five years to know how it is tolerated in humans, any side-effects it may cause and what might be an effective dose over five years.
- Trial name
- NCT07227285
- Testing
- Urodynamics, EG110A, Patient-reported Outcome
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Cyllene Therapeutics
Cognitive Developmental Delay
Neurocognitive Follow-Up (FU) Study
This is a follow-up study of a recently completed trial (17.14.INF) evaluating the growth of pre-term infants. Enrolled children will undergo neurocognitive assessments at 18- and 24-months of corrected age (CA).
- Trial name
- NCT04962035
- Testing
- Neurocognitive Follow-up
- Where
- 3 sites in Poland, Slovakia
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Primary Arthritis, Secondary Arthritis
A Multi-centre Study to Assess the Long-term Performance of the Silent Hip™ in Primary Total Hip Replacement Surgery
The purpose of this study is to monitor the performance and of the Silent Hip™ in the treatment of patients with hip joint disease requiring a total hip replacement.
- Trial name
- NCT01383824
- Testing
- Silent™ Hip
- Where
- 9 sites in Denmark, Germany and 3 more
- Volunteers
- 89 people
- Sponsor
- DePuy International
Hypertension, Pulmonary
Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension
The aim of this study is to monitor long-term safety and tolerability of iloprost aerosol inhalation therapy in patients suffering from pulmonary hypertension.
- Trial name
- NCT00185315
- Testing
- Ventavis (Iloprost, BAYQ6256)
- Where
- 16 sites in Belgium, France and 5 more
- Volunteers
- 71 people
- Sponsor
- Bayer
Orthopedic Disorder, Arthritis Shoulder
Blueprint® Mixed Reality Pilot Study
A pilot Single-Arm, Multicenter, Prospective, Post-Market 6 months Follow-Up Clinical Investigation to Evaluate the Safety and Effectiveness of the Blueprint Mixed Reality HOLOBLUEPRINT™ (HOLOBLUEPRINT™).
- Conditions
- Orthopedic Disorder, Arthritis Shoulder, Arthritis, Degenerative, Cuff Tear Arthropathy
- Trial name
- BLUEMR (NCT06080412)
- Where
- 4 sites in France
- Volunteers
- 44 people
- Sponsor
- Stryker Trauma and Extremities
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.